Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing
CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.
You may also be interested in...
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.